NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Wealthfront Corporation (“Wealthfront” or the “Company”) (NASDAQ: WLTH).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Wealthfront and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] ...

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  AppLovin Corporation (“AppLovin” or the “Company”) (NASDAQ: APP).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether AppLovin and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On Januar ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Oracle Corporation and its officers or directors, following significant stock price declines related to financial disclosures and debt financing plans [1]. Group 1: Financial Developments - On September 10, 2025, Oracle announced a $300 billion, five-year cloud computing contract with OpenAI to supply computing power [3]. - On November 13, 2025, Oracle sought to raise an additional $38 billion in debt to fund its AI initiatives, which included the construction of two data centers to support the Oracle-OpenAI agreement [3]. - Following the debt announcement, Oracle's stock price dropped by $9.42 per share, or 4.15%, closing at $217.57 on November 13, 2025 [3]. - During a December 10, 2025 earnings call, Oracle's Executive Vice President disclosed an expected increase in fiscal 2026 capital expenditures by $15 billion compared to previous forecasts [4]. - This announcement led to a further decline in Oracle's stock price by $24.16 per share, or 10.83%, closing at $198.85 on December 11, 2025 [4]. Group 2: Legal Investigation - Pomerantz LLP is actively investigating claims on behalf of Oracle investors regarding potential securities fraud or other unlawful practices by the company and its executives [1].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Atara Biotherapeutics, Inc. following a significant stock price drop after the FDA's Complete Response Letter regarding its drug EBVALLO™ [1][3]. Group 1: Company Overview - Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing therapies for patients with serious diseases [1]. - The company’s stock experienced a dramatic decline of 56.99%, falling $7.79 to close at $5.88 per share on January 12, 2026, after the FDA's announcement [3]. Group 2: FDA Response - On January 12, 2026, Atara announced that the FDA issued a Complete Response Letter (CRL) for its EBVALLO™ Biologics License Application (BLA) for treating Epstein-Barr virus positive post-transplant lymphoproliferative disease [3]. - The CRL indicated that the FDA could not approve the BLA in its current form, citing inadequacies in the evidence of effectiveness from the single arm ALLELE trial [3].

Core Viewpoint - Celestica Inc. is under investigation for potential securities fraud or unlawful business practices following a significant drop in its stock price due to news regarding a shift in assembly work for Google's AI servers [1][3]. Group 1: Investigation Details - Pomerantz LLP is investigating claims on behalf of investors of Celestica, focusing on whether the company and its officers/directors engaged in securities fraud or other unlawful practices [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation [1]. Group 2: Stock Performance - On January 22, 2026, news from Digitimes indicated that Google may shift assembly work for its tensor processing units to other suppliers, which could reduce Celestica's role in assembling Google's AI servers [3]. - Following this news, Celestica's stock price fell by $18.83 per share, representing a decline of 6.08%, closing at $290.92 per share [3].

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Beta Bionics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Ashford Hospitality Trust, Inc. and its officers or directors [1]. Group 1: Company Actions - On January 13, 2026, Ashford announced the extension of its Highland mortgage loan secured by 18 hotels and suspended preferred dividends to maintain liquidity while evaluating strategic alternatives [3]. - The suspension of dividends affects Series D, F, G, H, I, J, K, L, and M preferred stockholders as of December 31, 2025, with payments originally scheduled for January 15, 2026 [3]. Group 2: Market Reaction - Following the announcement regarding the mortgage loan and dividend suspension, Ashford's stock price decreased by $0.35 per share, representing an 8.1% decline, closing at $3.97 per share on January 13, 2026 [3].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Atlassian Corporation and its officers or directors [1] Group 1: Stock Performance and Analyst Opinions - On January 16, 2026, Citi reduced its price target for Atlassian stock from $240 to $210, citing concerns over the quality of revenue growth and the impact of code assistant platforms [3] - Following the downgrade, Atlassian's stock price dropped by $9.90, or 7.71%, closing at $118.55 per share on the same day [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving First Western Financial, Inc. and its officers or directors, following disappointing financial results that led to a significant drop in stock price [1][3]. Financial Performance - On January 22, 2026, First Western reported fourth-quarter earnings of $0.34 per share, which fell short of analyst expectations [3]. - Following the earnings report, First Western's stock price decreased by $2.40 per share, representing an 8.81% decline, closing at $24.83 per share on January 23, 2026 [3]. Legal Investigation - Pomerantz LLP is actively seeking claims from investors of First Western regarding possible securities fraud or other unlawful business practices [1]. - Investors are encouraged to contact Pomerantz LLP for more information about the class action investigation [2]. Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [4].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Cogent Communications Holdings, Inc. and its officers or directors [1] Financial Performance - On November 6, 2025, Cogent reported a year-over-year service revenue decline of nearly 6% for the third quarter of 2025 [3] - The company announced a significant dividend cut of 98%, reducing it from $1.015 per share to $0.02 per share [3] - Following the announcement, Cogent's stock price dropped by $13.35 per share, or 34.86%, closing at $24.95 per share on the same day [3]